ライフサイエンスコーパス: Gram-negative bacteremia

1 c decision making in pediatric patients with Gram-negative bacteremia.

2 ne expression are associated with subsequent Gram-negative bacteremia.

3 use of antibiotic treatment in patients with gram-negative bacteremia.

4 ed on blood culture pellets in patients with gram-negative bacteremia.

5 alent complex with GBOMP may protect against gram-negative bacteremia.

6 ne of the 3 subjects with urinary sources of gram-negative bacteremia.

7 (5.4 vs 6.4 days; P=.03) among patients with gram-negative bacteremia.

8 duration for individuals with uncomplicated gram-negative bacteremia.

9 ove time to optimal therapy in patients with gram-negative bacteremia.

10 xone to piperacillin-tazobactam in suspected gram-negative bacteremia.

11 o longer treatment duration in patients with gram-negative bacteremia.

12 ous complications were rare and consisted of gram-negative bacteremia (1.6%), gram-positive bacteremi

13 Among adults with uncomplicated gram-negative bacteremia, 30-day rates of clinical failu

14 bacteremia (14.3% vs. 10.9%, P = 0.000016), gram-negative bacteremia (7.6% vs. 4.9%, P = 0.000003),

15 rity were male (54%), had community-acquired gram-negative bacteremia (86%), urinary tract infection

16 In patients hospitalized with gram-negative bacteremia achieving clinical stability be

17 Gram-negative bacteremia after trauma is, in part, conse

18 Mice receiving 11 doses of morphine showed gram-negative bacteremia and bacterial growth in samples

19 itive blood culture bottles in patients with gram-negative bacteremia and found good concordance with

20 6 subjects with gastrointestinal sources of gram-negative bacteremia and none of the 3 subjects with

21 -positive bacteremia, from 5.3% to 41.9% for gram-negative bacteremia, and from 0.6% to 26.1% for fun

22 Using gram-negative bacteremia as an exemplar condition, we so

23 terobacteriaceae isolates from patients with gram-negative bacteremia at a 1,250-bed teaching hospita

24 Among episodes of gram-negative bacteremia between 2017 and 2020 from 6 ho

25 am-positive bacteremia than in patients with gram-negative bacteremia, but this difference was not st

26 t on the clinical management of 35.1% of all gram-negative bacteremia cases, demonstrating a greater

27 be enriched in a cohort of 180 patients with gram-negative bacteremia, compared with 229 healthy cont

28 ociated with increased hospital mortality in Gram-negative bacteremia complicated by severe sepsis or

29 cal trial including adults hospitalized with gram-negative bacteremia conducted in 3 Swiss tertiary c

30 on was compared between the subjects in whom Gram-negative bacteremia developed and those in whom it

31 r injury in 10 subjects in whom subsequently Gram-negative bacteremia developed matched to 26 subject

32 tive blood culture broths from patients with gram-negative bacteremia due to five target organisms at

33 In this cohort study of uncomplicated gram-negative bacteremia, early transition to oral antib

34 Among 6577 gram-negative bacteremia episodes, the likelihood of cov

35 We enrolled 148 patients with gram-negative bacteremia (Escherichia coli, n = 75; Kleb

36 Gram-negative bacteremia (GN-BSI) can cause significant

37 Gram-negative bacteremia (GNB) is a major cause of illne

38 h Staphylococcus aureus bacteremia (SAB) and gram-negative bacteremia (GNB) to compare the characteri

39 Among 202 episodes of gram-negative bacteremia, Gram stain reporting had an im

40 g pediatric patients (aged </=18 years) with gram-negative bacteremia hospitalized at the Johns Hopki

41 to multiple organ failure in human cases of gram-negative bacteremia; however, little is known regar

42 vational data from adults with uncomplicated gram-negative bacteremia in 4 hospitals in Copenhagen, D

43 We retrospectively reviewed cases of Gram-negative bacteremia in hospitalized patients over a

44 The use of beta-lactam monotherapy for gram-negative bacteremia in pediatric patients reduces s

45 ilation, high-level cytomegalovirus viremia, gram-negative bacteremia, invasive mold infection, acute

46 systems from 2016 to 2021 with uncomplicated gram-negative bacteremia involving an organism susceptib

47 Gram-negative bacteremia is a common infection that resu

48 Gram-negative bacteremia is a global health concern, and

49 Gram-negative bacteremia is a major cause of morbidity a

50 m and an aminoglycoside for the treatment of gram-negative bacteremia is commonly prescribed in pedia

51 Currently, the management of gram-negative bacteremia is determined by clinical judgm

52 Gram-negative bacteremia is highly fatal, and hospitaliz

53 atic infection and adverse outcomes, whereas gram-negative bacteremia is normally transient and short

54 appears to be differentially regulated after gram-negative bacteremia; LPS cleared by liver and lung

55 h Staphylococcus aureus bacteremia (n = 66), gram-negative bacteremia (n = 74), or noninfected contro

56 S. aureus (OR, 1.92; 95% CI, 1.12-3.29) and gram-negative bacteremia (OR, 2.21; 95% CI, 1.35-3.60).

57 xpression associated with the development of Gram-negative bacteremia, reflecting suppression of both

58 the detrimental inflammatory response during Gram-negative bacteremia remain poorly defined.

59 the availability of antimicrobial therapies, gram-negative bacteremia remains a significant cause of

60 neumoniae bacteremia.IMPORTANCEPatients with gram-negative bacteremia require urgent treatment with a

61 n-regulation of adaptive immune genes in the Gram-negative bacteremia subjects.

62 reflecting suppression of innate immunity in Gram-negative bacteremia subjects.

63 ucing antibiotic treatment for uncomplicated gram-negative bacteremia to 7 days is an important antib

64 cal target trial allocating individuals with gram-negative bacteremia to either short antibiotic trea

65 s retrospective study included patients with gram-negative bacteremia treated with intravenous colist

66 We observed that Gram-negative bacteremia was an independent risk factor

67 The incidence of Gram-negative bacteremia was significantly reduced in th

68 Inpatients with gram-negative bacteremia, who were afebrile and hemodyna